(Q36070775)

12 August 2017

1 reference

title

Severe asthma treatment: need for characterising patients (English)

1 reference

12 August 2017

0 references

Liam G Heaney

1

1 reference

12 August 2017

Douglas S Robinson

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

365

1 reference

12 August 2017

issue

9463

1 reference

12 August 2017

page(s)

974-976

1 reference

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Systematic assessment of difficult-to-treat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

1 reference

7 January 2021

Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Pseudo-steroid resistant asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Allergen avoidance in the treatment of asthma and atopic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Control of Exposure to Mite Allergen and Allergen-Impermeable Bed Covers for Adults with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

The mechanisms of aspirin-intolerant asthma and its management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Case-control study of severe life threatening asthma (SLTA) in adults: psychological factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971087-4

7 January 2021

10.1016/S0140-6736(05)71087-4

Identifiers

DOI

1 reference

12 August 2017

1 reference